GABAB Receptor Antibody Testing for Autoimmune Encephalitis Diagnosis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for diagnosing autoimmune encephalitis and epilepsy are inadequate, as they lack specificity and sensitivity, particularly in identifying the underlying cause, such as tumors associated with these conditions, which can lead to delayed or inappropriate treatment.

Innovation Solution

A method involving the testing of biological samples for the presence of antibodies to the GABA B receptor, specifically the B1 and B2 subunits, to diagnose autoimmune encephalitis, occult tumors causing encephalitis, or tumors causing epilepsy, using cerebrospinal fluid, serum, or plasma samples.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional diagnostic methods are used for autoimmune encephalitis and epilepsy, then the diagnostic process is simpler and less costly, but the diagnosis lacks specificity and sensitivity, leading to delayed or inappropriate treatment

Engineering Contradiction:
Improvediagnostic accuracyVSAvoiddiagnostic method complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The diagnostic approach is segmented into multiple specific antibody tests targeting different neuronal antigens (NMDAR, AMPAR, GABA A, GABA B, VGKC, GAD65). This segmentation allows for precise identification of specific autoimmune encephalitis subtypes, improving diagnostic accuracy while maintaining a systematic and organized diagnostic workflow that manages complexity through structured testing protocols

Inventive Principle:
Principle #1Segmentation

2Reliability

If conventional diagnostic methods are used, then the diagnostic workflow is faster and less resource-intensive, but the ability to identify underlying tumors is reduced

Engineering Contradiction:
Improvetumor identification reliabilityVSAvoiddiagnosis time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent implements preliminary comprehensive antibody screening across multiple neuronal antigen targets before finalizing the diagnosis. This preliminary action ensures that potential tumor-associated antibodies are detected early in the diagnostic process, allowing for timely tumor identification and intervention while establishing a thorough diagnostic foundation that prevents missed diagnoses

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The diagnostic process incorporates feedback loops where antibody test results guide further investigative actions. Positive antibody findings trigger targeted tumor screening and imaging, while negative results guide alternative diagnostic pathways. This feedback mechanism optimizes the balance between thoroughness and efficiency, ensuring tumor identification without unnecessary delays

Inventive Principle:
Principle #23Feedback

3Measurement precision

If comprehensive antibody testing is performed, then the diagnostic specificity and tumor detection improve, but the complexity and cost of the diagnostic process increase

Engineering Contradiction:
Improvedisease subtype identification accuracyVSAvoiddiagnostic implementation ease
Core Design Contradiction:
Measurement precisionVSEase of manufacture

Solution Approach 1:

The patent employs a universal diagnostic panel that tests for multiple neuronal antibody targets simultaneously using standardized assay methodologies. This multi-functional approach allows a single diagnostic workflow to address various autoimmune encephalitis subtypes and potential paraneoplastic syndromes, improving disease subtype identification accuracy while maintaining implementation ease through standardized protocols that can be performed in常规 clinical laboratories

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentEP2483417B1Methods for diagnosing and treating encephalitis or epilepsy
Publication Date: 2017.03.29 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
  • EP2483417B1 patent drawingFigure 1a~1d
  • EP2483417B1 patent drawingFigure 2a~2d
  • EP2483417B1 patent drawingFigure 3a~3c

AI summary

This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to a GABAB receptor. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to a GABAB receptor and treating a tumor associated with the disease.